Prior to joining Abingworth, Andrew had more than 10 years experience as an equity analyst in the pharmaceutical and biotechnology sectors. At Abingworth, he works across multiple strategies, including CCD, private investing and specialises in evaluating opportunities in public companies including VIPE investments. He is a fund manager for open market transactions and represents Abingworth on the boards of Adicet Bio, Entact Bio and Soleno. He was also an observer on the boards of HilleVax and Phathom.
He joined Abingworth in 2008 from HSBC Global Markets, where he was Senior Equity Analyst, Director, responsible for investment research in the mid-cap pharmaceutical sector. Previously, Andrew held biotechnology analyst positions at Credit Suisse and SG Cowen. He completed a PhD in Chemistry and Genetic Engineering at the BBSRC Institute of Plant Science, Norwich, and holds a BSc in Microbiology from King’s College London. Andrew qualified as a chartered accountant with KPMG.
